<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03599362</url>
  </required_header>
  <id_info>
    <org_study_id>17-01430</org_study_id>
    <nct_id>NCT03599362</nct_id>
  </id_info>
  <brief_title>Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer</brief_title>
  <official_title>Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-institutional, single arm phase II study of nivolumab, cabiralizumab and stereotactic&#xD;
      body radiotherapy (SBRT) in patients with LAUPC. The purpose of this study is to determine&#xD;
      the safety and tolerability of combined cabiralizumab, nivolumab and radiotherapy in the&#xD;
      treatment of locally advanced pancreatic cancer. Investigators will also estimate the&#xD;
      surgical resection rate following treatment with combined cabiralizumab, nivolumab and&#xD;
      radiotherapy in subjects with locally advanced unresectable pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PI departure from institution&#xD;
  </why_stopped>
  <start_date type="Actual">July 31, 2018</start_date>
  <completion_date type="Actual">June 15, 2020</completion_date>
  <primary_completion_date type="Actual">June 15, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Incidence of Unacceptable Toxicity</measure>
    <time_frame>24 Months</time_frame>
    <description>Measure of safety of combined cabiralizumab, nivolumab and radiotherapy in the treatment of locally advanced pancreatic cancer measured by unacceptable toxicity, which includes:&#xD;
Grade 3 fatigue lasting &gt; 2 Weeks&#xD;
Grade 3 Nausea lasting &gt; 7 days despite maximal medical management&#xD;
Grade 3 or more anorexia&#xD;
Grade 3 or more vomiting&#xD;
Grade 3 or more diarrhea&#xD;
Grade 3 or more pancreatitis&#xD;
Grade 3 abdominal pain&#xD;
Grade 3 or more radiation dermatitis&#xD;
Grade 3 or more GI hemorrhage&#xD;
Grade 3 or more GI fistula&#xD;
Grade 3 or more GI stenosis&#xD;
Grade 3 or more GI perforation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Proceeded to Surgical Resection</measure>
    <time_frame>24 Months</time_frame>
    <description>Surgical resection rate following treatment with combined cabiralizumab, nivolumab and radiotherapy in subjects with locally advanced unresectable pancreatic cancer.&#xD;
This will be measured by tabulating adverse events</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Multi Agent Chemotherapy Cancer Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be enrolled into this study following completion of 2-6 months of multi agent chemotherapy with documentation of stable or responsive disease.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab + Cabiralizumab</intervention_name>
    <description>Will be administered on Day 1 and Day 14; Subjects will continue treatment every 2 weeks with subsequent imaging every 8 weeks.</description>
    <arm_group_label>Multi Agent Chemotherapy Cancer Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Body Radiotherapy (SBRT)</intervention_name>
    <description>Patients will be simulated supine with the addition of a 4D C T if appropriate. A stereotactic immobilization device with abdominal compression will be used.</description>
    <arm_group_label>Multi Agent Chemotherapy Cancer Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed locally advanced, unresectable pancreatic cancer as defined&#xD;
             by NCCN Guidelines 3.2017&#xD;
&#xD;
          -  Locally advanced unresectable disease is defined by the NCCN as:&#xD;
&#xD;
          -  Tumors of the head that have greater than 180 degrees of SMA encasement or any celiac&#xD;
             abutment, unreconstructable SMV or portal occlusion, or aortic invasion or encasement.&#xD;
&#xD;
          -  Tumors of the body with SMA or celiac encasement of greater than 180 degrees,&#xD;
             unreconstructable SMV or portal occlusion, or aortic invasion.&#xD;
&#xD;
          -  Tumors of the tail with SMA or celiac encasement of greater than 180 degrees.&#xD;
             Irrespective of location, all tumors with evidence of nodal metastasis outside of the&#xD;
             resection field are deemed unresectable.&#xD;
&#xD;
          -  Patients must agree to pretreatment and on treatment tumor biopsy&#xD;
&#xD;
          -  ECOG performance status of 0 or 1&#xD;
&#xD;
          -  Completion of at least 2 months, but no more than 6 months of standard induction&#xD;
             chemotherapy for LAPC, which must include either FOLFIRINOX or gemcitabine and nab-&#xD;
             paclitaxel, preferably within 2-4 weeks but no longer than 8 weeks.&#xD;
&#xD;
          -  Normal organ and marrow function as defined below:&#xD;
&#xD;
          -  absolute neutrophil count ≥ 1,500/mm3&#xD;
&#xD;
          -  platelets ≥ 100,000/mm3&#xD;
&#xD;
          -  total bilirubin ≤ 1.5 x institutional upper limit of normal (except participants with&#xD;
             Gilbert's syndrome who must have normal direct bilirubin)&#xD;
&#xD;
          -  AST(SGOT) and ALT(SGPT) ≤ 2 × institutional upper limit of normal&#xD;
&#xD;
          -  creatinine ≤ 1.5 mg/ dL OR&#xD;
&#xD;
          -  creatinine clearance≥ 30 mL/min (as estimated by Cockcroft Gault Equation)&#xD;
&#xD;
          -  Ability to understand and sign a written informed consent document. Participant must&#xD;
             have willingness and ability to comply with scheduled visits, treatment plans,&#xD;
             laboratory tests and other study procedures.&#xD;
&#xD;
          -  Women of childbrearing potential (WOCBP) must have a negative serum or urine pregnancy&#xD;
             test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to&#xD;
             the start of study treatment.&#xD;
&#xD;
          -  WOCBP must agree to follow instructions for method(s) of contraception for the&#xD;
             duration of treatment with study treatment(s) and for a total of 5 months&#xD;
             post-treatment completion.&#xD;
&#xD;
          -  Males who are sexually active with WOCBP must agree to follow instructions for&#xD;
             method(s) of contraception (see appendix 1) for the duration of treatment with study&#xD;
             treatment(s) and for a total of 7 months posttreatment completion. In addition, male&#xD;
             participants must be willing to refrain from sperm donation during this time.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Resectable, borderline resectable or metastatic disease&#xD;
&#xD;
          -  Interstitial lung disease that is symptomatic or may interfere with the detection or&#xD;
             management of suspected treatment-related pulmonary toxicity.&#xD;
&#xD;
          -  Participants with a condition requiring systemic treatment with either corticosteroids&#xD;
             (&gt; 10 mg daily prednisone equivalents) or other immunosuppressive medications within&#xD;
             14 days of study treatment administration except for adrenal replacement steroid doses&#xD;
             &gt; 10 mg daily prednisone equivalent in the absence of active autoimmune disease.&#xD;
&#xD;
        Note: Treatment with a short course of steroids (&lt; 5 days) up to 7 days prior to initiating&#xD;
        study treatment is permitted.&#xD;
&#xD;
          -  Current or history of clinically significant muscle disorders (eg, myositis), recent&#xD;
             unresolved muscle injury, or any condition known to elevate serum CK levels&#xD;
&#xD;
          -  Uncontrolled or significant cardiovascular disease including, but not limited to, any&#xD;
             of the following:&#xD;
&#xD;
          -  Myocardial infarction or stroke/transient ischemic attack within the past 6 months&#xD;
&#xD;
          -  Uncontrolled angina within the past 3 months&#xD;
&#xD;
          -  Any history of clinically significant arrhythmias (such as ventricular tachycardia,&#xD;
             ventricular fibrillation, or torsades de pointes)&#xD;
&#xD;
          -  History of other clinically significant heart disease (eg, cardiomyopathy, congestive&#xD;
             heart failure with New York Heart Association functional classification III to IV,&#xD;
             pericarditis, significant pericardial effusion, or myocarditis)&#xD;
&#xD;
          -  Cardiovascular disease-related requirement for daily supplemental oxygen therapy.&#xD;
&#xD;
          -  Evidence of uncontrolled, active infection, requiring parenteral anti-bacterial,&#xD;
             anti-viral or anti-fungal therapy ≤ 7 days prior to administration of study&#xD;
             medication.&#xD;
&#xD;
          -  Any uncontrolled inflammatory GI disease including Crohn's Disease and ulcerative&#xD;
             colitis.&#xD;
&#xD;
          -  Participants with active, known, or suspected autoimmune disease. Participants with&#xD;
             vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune&#xD;
             condition only requiring hormone replacement, euthyroid participants with a history of&#xD;
             Grave's disease (participants with suspected autoimmune thyroid disorders must be&#xD;
             negative for thyroglobulin and thyroid peroxidase antibodies and thyroid stimulating&#xD;
             immunoglobulin prior to first dose of study treatment), psoriasis not requiring&#xD;
             systemic treatment, or conditions not expected to recur in the absence of an external&#xD;
             trigger are permitted to enroll after discussing with the Principal Investigator.&#xD;
&#xD;
          -  Concomitant use of statins while on study. However, a patient using statins for over 3&#xD;
             months prior to study drug administration and in stable status without CK rise may be&#xD;
             permitted to enroll.&#xD;
&#xD;
          -  Non-oncology vaccine therapies for prevention of infectious diseases (eg, human&#xD;
             papillomay virus vaccine) within 4 weeks of study drug administration. The inactivated&#xD;
             seasonal influenza vaccine can be given to patients before treatment and while on&#xD;
             therapy without restriction. Influenza vaccines containing live virus or other&#xD;
             clinically indicated vaccinations for infectious diseases (ie, pneumovax, varicella,&#xD;
             etc) may be permitted, but must be discussed with the principal investigator and may&#xD;
             require a study drug washout period prior to and after administration of vaccine.&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV), known active hepatitis A, or known hepatitis&#xD;
             B or C infection.&#xD;
&#xD;
          -  History of acute diverticulitis within the last 6 months, or current chronic diarrhea&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) with either a positive or no pregnancy test&#xD;
             (serum or urine) at baseline. (Postmenopausal women must have been amenorrheic for at&#xD;
             least 12 months to be considered of non-childbearing potential.)&#xD;
&#xD;
          -  WOCBP who are unwilling or unable to use an acceptable method to minimize the risk of&#xD;
             pregnancy (see appendix 1) for the entire study period and for at least 5 months after&#xD;
             the last dose of investigational product. WOCBP who are continuously not&#xD;
             heterosexually active are also exempt from contraceptive requirements, but still must&#xD;
             undergo pregnancy testing as described in section - Sexually active fertile men not&#xD;
             using effective birth control if their partners are WOCBP&#xD;
&#xD;
          -  History of primary immunodeficiency.&#xD;
&#xD;
          -  History of organ allograft or allogeneic bone marrow transplant.&#xD;
&#xD;
          -  Any prior radiation therapy, immunotherapy, or biologic ('targeted') therapy for&#xD;
             treatment of the patient's pancreatic tumor. Patient should have received either&#xD;
             FOLFIRINOX or gemcitabine and nab-paclitaxel prior to enrollment.&#xD;
&#xD;
          -  Treatment for other invasive carcinomas within the last five years who are at greater&#xD;
             than 5% risk of recurrence at time of eligibility screening. Carcinoma in-situ and&#xD;
             basal cell carcinoma/ squamous cell carcinoma of the skin are allowed.&#xD;
&#xD;
          -  Participation in any investigational drug study within 4 weeks preceding the start of&#xD;
             study treatment.&#xD;
&#xD;
          -  Major surgery, excluding laparoscopy, within 4 weeks of the start of study treatment,&#xD;
             without complete recovery.&#xD;
&#xD;
          -  History of allergy to study treatments or any of its components&#xD;
&#xD;
          -  Known history of sensitivity to infusions containing Tween 20 (polysorbate 20) and&#xD;
             Tween 80 (polysorbate 80)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deirdre Cohen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 10, 2018</study_first_submitted>
  <study_first_submitted_qc>July 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <results_first_submitted>June 17, 2021</results_first_submitted>
  <results_first_submitted_qc>September 22, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 19, 2021</results_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 28, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/62/NCT03599362/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Multi Agent Chemotherapy Cancer Patients</title>
          <description>Subjects will be enrolled into this study following completion of 2-6 months of multi agent chemotherapy with documentation of stable or responsive disease.&#xD;
Nivolumab + Cabiralizumab: Will be administered on Day 1 and Day 14; Subjects will continue treatment every 2 weeks with subsequent imaging every 8 weeks.&#xD;
Stereotactic Body Radiotherapy (SBRT): Patients will be simulated supine with the addition of a 4D C T if appropriate. A stereotactic immobilization device with abdominal compression will be used.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Screen Failure</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Multi Agent Chemotherapy Cancer Patients</title>
          <description>Subjects will be enrolled into this study following completion of 2-6 months of multi agent chemotherapy with documentation of stable or responsive disease.&#xD;
Nivolumab + Cabiralizumab: Will be administered on Day 1 and Day 14; Subjects will continue treatment every 2 weeks with subsequent imaging every 8 weeks.&#xD;
Stereotactic Body Radiotherapy (SBRT): Patients will be simulated supine with the addition of a 4D C T if appropriate. A stereotactic immobilization device with abdominal compression will be used.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" lower_limit="37" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Incidence of Unacceptable Toxicity</title>
        <description>Measure of safety of combined cabiralizumab, nivolumab and radiotherapy in the treatment of locally advanced pancreatic cancer measured by unacceptable toxicity, which includes:&#xD;
Grade 3 fatigue lasting &gt; 2 Weeks&#xD;
Grade 3 Nausea lasting &gt; 7 days despite maximal medical management&#xD;
Grade 3 or more anorexia&#xD;
Grade 3 or more vomiting&#xD;
Grade 3 or more diarrhea&#xD;
Grade 3 or more pancreatitis&#xD;
Grade 3 abdominal pain&#xD;
Grade 3 or more radiation dermatitis&#xD;
Grade 3 or more GI hemorrhage&#xD;
Grade 3 or more GI fistula&#xD;
Grade 3 or more GI stenosis&#xD;
Grade 3 or more GI perforation</description>
        <time_frame>24 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Multi Agent Chemotherapy Cancer Patients</title>
            <description>Subjects will be enrolled into this study following completion of 2-6 months of multi agent chemotherapy with documentation of stable or responsive disease.&#xD;
Nivolumab + Cabiralizumab: Will be administered on Day 1 and Day 14; Subjects will continue treatment every 2 weeks with subsequent imaging every 8 weeks.&#xD;
Stereotactic Body Radiotherapy (SBRT): Patients will be simulated supine with the addition of a 4D C T if appropriate. A stereotactic immobilization device with abdominal compression will be used.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Incidence of Unacceptable Toxicity</title>
          <description>Measure of safety of combined cabiralizumab, nivolumab and radiotherapy in the treatment of locally advanced pancreatic cancer measured by unacceptable toxicity, which includes:&#xD;
Grade 3 fatigue lasting &gt; 2 Weeks&#xD;
Grade 3 Nausea lasting &gt; 7 days despite maximal medical management&#xD;
Grade 3 or more anorexia&#xD;
Grade 3 or more vomiting&#xD;
Grade 3 or more diarrhea&#xD;
Grade 3 or more pancreatitis&#xD;
Grade 3 abdominal pain&#xD;
Grade 3 or more radiation dermatitis&#xD;
Grade 3 or more GI hemorrhage&#xD;
Grade 3 or more GI fistula&#xD;
Grade 3 or more GI stenosis&#xD;
Grade 3 or more GI perforation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Proceeded to Surgical Resection</title>
        <description>Surgical resection rate following treatment with combined cabiralizumab, nivolumab and radiotherapy in subjects with locally advanced unresectable pancreatic cancer.&#xD;
This will be measured by tabulating adverse events</description>
        <time_frame>24 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Multi Agent Chemotherapy Cancer Patients</title>
            <description>Subjects will be enrolled into this study following completion of 2-6 months of multi agent chemotherapy with documentation of stable or responsive disease.&#xD;
Nivolumab + Cabiralizumab: Will be administered on Day 1 and Day 14; Subjects will continue treatment every 2 weeks with subsequent imaging every 8 weeks.&#xD;
Stereotactic Body Radiotherapy (SBRT): Patients will be simulated supine with the addition of a 4D C T if appropriate. A stereotactic immobilization device with abdominal compression will be used.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Proceeded to Surgical Resection</title>
          <description>Surgical resection rate following treatment with combined cabiralizumab, nivolumab and radiotherapy in subjects with locally advanced unresectable pancreatic cancer.&#xD;
This will be measured by tabulating adverse events</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Multi Agent Chemotherapy Cancer Patients</title>
          <description>Subjects will be enrolled into this study following completion of 2-6 months of multi agent chemotherapy with documentation of stable or responsive disease.&#xD;
Nivolumab + Cabiralizumab: Will be administered on Day 1 and Day 14; Subjects will continue treatment every 2 weeks with subsequent imaging every 8 weeks.&#xD;
Stereotactic Body Radiotherapy (SBRT): Patients will be simulated supine with the addition of a 4D C T if appropriate. A stereotactic immobilization device with abdominal compression will be used.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear and Labyrinth Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Ear Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Periorbital Edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Edema Face</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Gait Disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>General Disorders and Administration Site Conditions</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Localized Edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Increase in ALT</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Increase in AST</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Increase in Alkaline Phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Increase in CPK</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Increase in Creatinine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Increase in Lipase</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Decrease in Lymphocyte Count</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Decrease in Platelet Count</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Increase in Serum Amylase</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Decrease in WBC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Epis Taxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Sore Throat</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash Maculo</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Fraustina Hsu</name_or_title>
      <organization>NYU Langone Health</organization>
      <phone>6467547124</phone>
      <email>Fraustina.Hsu@nyulangone.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

